Dazodalibep is under clinical development by Horizon Therapeutics and currently in Phase III for Rheumatoid Arthritis. According to GlobalData, Phase III drugs for Rheumatoid Arthritis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dazodalibep’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dazodalibep (VIB-4920, MEDI-4920) is under development for the treatment of focal segmental glomerulosclerosis, kidney transplant rejection, rheumatoid arthritis and Sjogren's syndrome. It is administered by intravenous route. The drug candidate is a biological agent derived from third fibronectin type III domain of human tenascin C antagonizing the CD40 ligand. It is an anti-CD40L-Tn3 fusion protein.
Horizon Therapeutics overview
Horizon Therapeutics formerly Horizon Pharma, is a pharmaceutical company, which develops and commercializes medical products for the treatment of rare, autoimmune, arthritis and severe inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. A few of the company’s marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Pennsaid, Procysbi, Quinsair, Ravicti, Rayos, Tepezza, Uplinza, and Vimovo. Horizon Therapeutics provides products and services to patients and healthcare professionals in the US. The company operates through offices in the US, Switzerland, Luxembourg, Bermuda, Germany, Canada, and Israel. Horizon Therapeutics is headquartered in Dublin, Ireland.
For a complete picture of Dazodalibep’s drug-specific PTSR and LoA scores, buy the report here.